Tanja Sofie Hansen

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial

Thomas F. Dejgaard, Christian S. Frandsen, Tanja Sofie Hansen et al. · The Lancet Diabetes & Endocrinology · 2015 · 178 citations

Medicine, Endocrinology, Pharmacotherapy +12

Environmental factors in inflammatory bowel disease: A case-control study based on a Danish inception cohort

Tanja Sofie Hansen, Tine Jess, Ida Vind et al. · Journal of Crohn s and Colitis · 2011 · 173 citations

Medicine, Health Sciences, Orthopaedic Surgery +14

Infliximab for Inflammatory Bowel Disease in Denmark 1999–2005: Clinical Outcome and Follow-Up Evaluation of Malignancy and Mortality

Sarah Caspersen, Lene Riis, Natalia Pedersen et al. · Clinical Gastroenterology and Hepatology · 2008 · 140 citations · Full text

Medicine, Immunology, Internal Medicine +14

Genetic and environmental factors as predictors of disease severity and extent at time of diagnosis in an inception cohort of inflammatory bowel disease, Copenhagen County and City 2003–2005

Ida Vind, Lene Riis, Cathrine Jespersgaard et al. · Journal of Crohn s and Colitis · 2008 · 27 citations · Full text

Medicine, Genetics, Immunology +17

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study

Thomas F. Dejgaard, Filip K. Knop, Lise Tarnow et al. · BMJ Open · 2015 · 15 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17